Compare FMX & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMX | RMD |
|---|---|---|
| Founded | 1890 | 1989 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1B | 36.8B |
| IPO Year | 1998 | N/A |
| Metric | FMX | RMD |
|---|---|---|
| Price | $107.46 | $230.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $108.83 | ★ $293.70 |
| AVG Volume (30 Days) | 345.3K | ★ 890.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.67% | 1.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.25 | $10.64 |
| Revenue Next Year | $8.35 | $7.38 |
| P/E Ratio | $40.94 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.08 | $199.92 |
| 52 Week High | $116.09 | $293.81 |
| Indicator | FMX | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 29.11 |
| Support Level | $104.99 | N/A |
| Resistance Level | $115.35 | $260.21 |
| Average True Range (ATR) | 2.67 | 5.36 |
| MACD | -0.76 | -3.04 |
| Stochastic Oscillator | 15.26 | 2.35 |
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.